Novo Nordisk's US$3.1 billion Ablynx bid rejected by Belgian biotech


COPENHAGEN/BRUSSELS: Denmark's Novo Nordisk, the world's biggest maker of insulin, went public with a 2.6 billion euro bid for Belgian biotech group Ablynx on Monday as it seeks to bolster its treatments for rare blood disorders. Ablynx said it rejected Novo's latest takeover approach and analysts predict the Danish group, whose new chief executive is seeking growth by buying drugs developed by competitors, might face counterbidders and would need to raise its bid.



from Biotech News